Whales with a lot of money to spend have taken a noticeably bearish stance on Moderna.
Looking at options history for Moderna MRNA we detected 21 trades.
If we consider the specifics of each trade, it is accurate to state that 19% of the investors opened trades with bullish expectations and 80% with bearish.
From the overall spotted trades, 6 are puts, for a total amount of $385,634 and 15, calls, for a total amount of $725,250.
Predicted Price Range
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $75.0 to $175.0 for Moderna over the recent three months.
Volume & Open Interest Development
In today's trading context, the average open interest for options of Moderna stands at 1831.53, with a total volume reaching 8,276.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Moderna, situated within the strike price corridor from $75.0 to $175.0, throughout the last 30 days.
Moderna Option Volume And Open Interest Over Last 30 Days
Biggest Options Spotted:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|
| MRNA | PUT | TRADE | BULLISH | 01/19/24 | $80.00 | $89.4K | 3.8K | 153 |
| MRNA | PUT | SWEEP | BEARISH | 01/17/25 | $75.00 | $88.8K | 1.9K | 247 |
| MRNA | PUT | SWEEP | BEARISH | 06/21/24 | $80.00 | $82.0K | 2.2K | 11 |
| MRNA | CALL | SWEEP | BEARISH | 12/22/23 | $93.00 | $81.8K | 579 | 1.4K |
| MRNA | CALL | SWEEP | BULLISH | 01/17/25 | $120.00 | $73.2K | 1.7K | 40 |
About Moderna
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
After a thorough review of the options trading surrounding Moderna, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
Current Position of Moderna
- With a volume of 4,210,419, the price of MRNA is up 1.52% at $87.5.
- RSI indicators hint that the underlying stock may be approaching overbought.
- Next earnings are expected to be released in 63 days.
Professional Analyst Ratings for Moderna
A total of 2 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $86.0.
- An analyst from Canaccord Genuity has revised its rating downward to Hold, adjusting the price target to $82.
- Maintaining their stance, an analyst from JP Morgan continues to hold a Neutral rating for Moderna, targeting a price of $90.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Moderna with Benzinga Pro for real-time alerts.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
